恩帕吉菲
医学
心力衰竭
心脏病学
内科学
射血分数
收缩性
内皮功能障碍
心功能曲线
炎症
糖尿病
2型糖尿病
内分泌学
作者
Rio P. Juni,Diederik W.D. Kuster,Max Goebel,Michiel Helmes,René J.P. Musters,Jolanda van der Velden,Pieter Koolwijk,Walter J. Paulus,Victor W.M. van Hinsbergh
标识
DOI:10.1016/j.jacbts.2019.04.003
摘要
The positive findings of the EMPA-REG OUTCOME trial (Randomized, Placebo-Controlled Cardiovascular Outcome Trial of Empagliflozin) on heart failure (HF) outcome in patients with type 2 diabetes mellitus suggest a direct effect of empagliflozin on the heart. These patients frequently have HF with preserved ejection fraction (HFpEF), in which a metabolic risk-related pro-inflammatory state induces cardiac microvascular endothelial cell (CMEC) dysfunction with subsequent cardiomyocyte (CM) contractility impairment. This study showed that CMECs confer a direct positive effect on contraction and relaxation of CMs, an effect that requires nitric oxide, is diminished after CMEC stimulation with tumor necrosis factor-α, and is restored by empagliflozin. Our findings on the effect of empagliflozin on CMEC-mediated preservation of CM function suggests that empagliflozin can be used to treat the cardiac mechanical implications of microvascular dysfunction in HFpEF.
科研通智能强力驱动
Strongly Powered by AbleSci AI